We are live on ! Find out more
JUNO

Juno Therapeutics, Inc.
JUNO

Delisted

JUNO was delisted on the 5th of March, 2018.

Back to rankings

2 hedge funds and large institutions have $166K invested in Juno Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 232 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 237 → 2 (-235)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $3.7B → $166K (-$3.7B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 232

Holders
2
Holders Change
-235
Holders Change %
-99.16%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
232
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$482M
2
CM
Crestline Management
Texas
-$349M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$320M
4
Capital International Investors
Capital International Investors
California
-$287M
5
BlackRock
BlackRock
New York
-$221M
Name Holding Trade Value Shares
Change 		Change in
Stake
SEC
101
Seven Eight Capital
New York
– -$2.08M -45,532 Closed
SGA
102
Sector Gamma AS
Norway
– -$1.98M -43,400 Closed
BG
103
Bellevue Group
Switzerland
– -$1.92M -41,900 Closed
Kayne Anderson Rudnick Investment Management
104
Kayne Anderson Rudnick Investment Management
California
– -$1.85M -40,510 Closed
TD Asset Management
105
TD Asset Management
Ontario, Canada
– -$1.81M -39,700 Closed
PC
106
Polar Capital
United Kingdom
– -$1.71M -37,500 Closed
Federated Hermes
107
Federated Hermes
Pennsylvania
– -$1.65M -36,102 Closed
B
108
Bailard
California
– -$1.65M -36,000 Closed
SGH
109
Sivik Global Healthcare
Connecticut
– -$1.6M -35,000 Closed
OCM
110
Orser Capital Management
Texas
– -$1.58M -34,240 Closed
AllianceBernstein
111
AllianceBernstein
Tennessee
– -$1.56M -34,170 Closed
Two Sigma Advisers
112
Two Sigma Advisers
New York
– -$1.54M -33,761 Closed
EWM
113
Evercore Wealth Management
New York
– -$1.47M -32,062 Closed
PA
114
Profund Advisors
Maryland
– -$1.45M -31,805 Closed
Wolverine Trading
115
Wolverine Trading
Illinois
– -$1.42M -31,112 Closed
MCM
116
McKinley Capital Management
Alaska
– -$1.42M -31,041 Closed
QIM
117
Quantitative Investment Management
Virginia
– -$1.39M -30,400 Closed
AG
118
Aperio Group
California
– -$1.37M -29,949 Closed
CIA
119
Capital Impact Advisors
Massachusetts
– -$1.26M -27,602 Closed
Teacher Retirement System of Texas
120
Teacher Retirement System of Texas
Texas
– -$1.23M -26,830 Closed
PIM
121
Partner Investment Management
California
– -$1.19M -26,066 Closed
Principal Financial Group
122
Principal Financial Group
Iowa
– -$1.16M -25,372 Closed
SCM
123
Stevens Capital Management
Pennsylvania
– -$1.16M -25,333 Closed
VIA
124
Vident Investment Advisory
Georgia
– -$1.43M -25,207 Closed
AQR Capital Management
125
AQR Capital Management
Connecticut
– -$976K -21,358 Closed
3 4
5
6 7

JUNO Hedge Fund Activity: Q1 2018 in Review

2 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q1 2018, worth a combined $166K — down 100% from $3.7B a quarter earlier.

Sellers outnumbered buyers: 232 funds closed out of JUNO and 0 opened new positions — a net loss of 232 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $482M sold.

  • 2 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q1 2018, down from 237 in Q4 2017.
  • Funds reported $166K of Juno Therapeutics, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Juno Therapeutics, Inc. positions in Q1 2018 and 232 closed out, a net change of -232 holders.
  • The largest Juno Therapeutics, Inc. seller in Q1 2018 was Baillie Gifford & Co, an estimated $482M sold.

Based on aggregated 13F filings for Q1 2018.